This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CTI BioPharma Croissance future

Future contrôle des critères 5/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de CTI BioPharma.

Informations clés

60.0%

Taux de croissance des bénéfices

61.5%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.5%
Taux de croissance des recettes	34.0%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Good
Dernière mise à jour	27 Jun 2023

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch

Aug 17

CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M

Aug 08

CTI BioPharma: Approval Is Great, Now There's The Follow Through

Jul 19

CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis

Jul 07

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:CTIC - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	309	99	N/A	N/A	4
12/31/2024	221	36	N/A	N/A	6
12/31/2023	117	-39	N/A	N/A	4
3/31/2023	76	-69	-82	-82	N/A
12/31/2022	54	-93	-81	-81	N/A
9/30/2022	33	-112	-96	-96	N/A
6/30/2022	15	-121	-101	-101	N/A
3/31/2022	2	-118	-98	-98	N/A
12/31/2021	N/A	-98	-85	-85	N/A
9/30/2021	N/A	-76	-66	-66	N/A
6/30/2021	N/A	-63	-57	-57	N/A
3/31/2021	N/A	-58	-49	-49	N/A
12/31/2020	N/A	-52	-42	-42	N/A
9/30/2020	N/A	-46	-43	-43	N/A
6/30/2020	2	-44	-37	-37	N/A
3/31/2020	3	-41	-35	-35	N/A
12/31/2019	3	-40	-28	-28	N/A
9/30/2019	17	-31	-29	-29	N/A
6/30/2019	16	-36	-35	-35	N/A
3/31/2019	16	-36	-41	-41	N/A
12/31/2018	26	-29	-40	-40	N/A
9/30/2018	13	-45	-38	-38	N/A
6/30/2018	14	-42	-46	-46	N/A
3/31/2018	35	-29	-33	-33	N/A
12/31/2017	25	-45	-39	-39	N/A
9/30/2017	34	-37	-43	-43	N/A
6/30/2017	37	-54	-36	-36	N/A
3/31/2017	22	-75	-62	-62	N/A
12/31/2016	57	-52	N/A	-77	N/A
9/30/2016	60	-74	N/A	-84	N/A
6/30/2016	56	-78	N/A	-95	N/A
3/31/2016	50	-91	N/A	-94	N/A
12/31/2015	16	-123	N/A	-95	N/A
9/30/2015	23	-138	N/A	-69	N/A
6/30/2015	61	-101	N/A	-50	N/A
3/31/2015	61	-96	N/A	-43	N/A
12/31/2014	60	-96	N/A	-40	N/A
9/30/2014	75	-42	N/A	-33	N/A
6/30/2014	36	-69	N/A	-44	N/A
3/31/2014	35	-59	N/A	-41	N/A
12/31/2013	35	-50	N/A	-36	N/A
9/30/2013	2	-79	N/A	-63	N/A
6/30/2013	1	-77	N/A	-60	N/A
3/31/2013	1	-117	N/A	-59	N/A
12/31/2012	N/A	-115	N/A	-63	N/A
9/30/2012	N/A	-114	N/A	-51	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CTIC devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.1% ).

Bénéfices vs marché: CTIC devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: CTIC devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CTIC ( 34% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CTIC ( 34% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CTIC devrait être élevé dans 3 ans

This company listing is no longer active

CTI BioPharma Croissance future

Future contrôle des critères 5/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from NASDAQ Composite Index

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P TMI Index

CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Small Cap Comp Value Index

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

CTI BioPharma Corp. to Report Q3, 2022 Results on Nov 07, 2022

CTI BioPharma Corp. Announces Executive Changes

CTI BioPharma Corp. Announces Presentation of New Anemia Benefit Data from Pacritinib Program At the Society of Hematologic Oncology Tenth Annual Meeting

CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M

CTI BioPharma Corp. to Report Q2, 2022 Results on Aug 08, 2022

CTI BioPharma: Approval Is Great, Now There's The Follow Through

CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis

CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset

CTI BioPharma Corp., Annual General Meeting, Jun 01, 2022

National Comprehensive Cancer Network Recommends CTI BioPharma Corp.'s VONJO™ (pacritinib) for the Treatment of Myeloproliferative Neoplasms

CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. appoints James K. Fong as senior vice president and chief commercial officer

CTI BioPharma Corp. Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

CTI BioPharma: A Speculative Buy Into The PDUFA Date

CTI BioPharma: Long And Troubled History, Finally Approaching Approval

CTI BioPharma Corp. Announces Extension of FDA Review Period for Pacritinib in Myelofibrosis with Severe Thrombocytopenia

CTI BioPharma Corp. Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis

FDA grants 'priority review' status to CTI Biopharma's pacritinib NDA

CTI BioPharma initiated buy at Stifel; cites potential in myelofibrosis

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. to Report Q4, 2020 Results on Mar 17, 2021

CTI BioPharma: Accelerated Approval Pathway Looks Attractive

Cti Biopharma Corp. Announces Publication of Article Highlighting Pacritinib Data from the Pac203 Phase 2 Study in Myelofibrosis in Blood Advances

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. to Report Q3, 2020 Results on Nov 10, 2020

CTI BioPharma Corp. Initiates Rolling Submission of New Drug Application for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia

CTI BioPharma to Submit a New Drug Application (NDA) for the Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia

CTI BioPharma Corp. Contemplates Bankruptcy

Earnings released

New 90-day high - US$1.60

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance